LIVE
LIVE GMP
Core4 Engineers Ltd₹0·Jio Platforms Ltd₹+243·Paras Healthcare Ltd₹+8·BLS Polymers Ltd₹+35·Shellz India Ltd₹+38·Tonbo Imaging India Ltd₹+490·Zetwerk Manufacturing Business Ltd₹+5·Bonfiglioli Transmissions Ltd₹+110·Sahajanand Medical Technologies Ltd₹+22·Ravita Engineering Services Ltd₹+3·Fusion CX Ltd₹+5·HD Fire Protect Ltd₹+80·Vaibhav Vyapaar Ltd₹0·R.K.Fashion Accessories Ltd₹0·Core4 Engineers Ltd₹0·Jio Platforms Ltd₹+243·Paras Healthcare Ltd₹+8·BLS Polymers Ltd₹+35·Shellz India Ltd₹+38·Tonbo Imaging India Ltd₹+490·Zetwerk Manufacturing Business Ltd₹+5·Bonfiglioli Transmissions Ltd₹+110·Sahajanand Medical Technologies Ltd₹+22·Ravita Engineering Services Ltd₹+3·Fusion CX Ltd₹+5·HD Fire Protect Ltd₹+80·Vaibhav Vyapaar Ltd₹0·R.K.Fashion Accessories Ltd₹0·
Paras Healthcare Ltd
CLOSED
NSE & BSE
Bookbuilding IPO
Fresh capital cum OFS
Paras Healthcare IPO GMP
GREY MARKET
PREMIUM
₹
+ 8
+1% expected return
EST. LISTING
PRICE
₹701
Issue Price: ₹
693
Issue Price
₹693
Face Value
₹1
Lot Size
21 shares
IPO Size
Agg. upto ₹1,450 Cr
Open Date
21 Oct 2026
Close Date
23 Oct 2026
Allotment
26 Oct 2026
Listing Date
28 Oct 2026
Exchange
NSE & BSE
Paras Healthcare IPO Details: Price, Dates & Financials
The Paras Healthcare IPO GMP strength score is 4 out of 10, which the dashboard rates as Moderate. The Paras Healthcare IPO valuation is tagged Moderate. The Paras Healthcare IPO is subscribed 2.34 times overall so far. Amounts are calculated at the upper price band of ₹693.
IPO Analytics Dashboard
LIVE
Paras Healthcare IPO GMP Insights
Valuation
Moderate
Paras Healthcare IPO GMP Strength Score
4
/ 10
Moderate
0–3 Weak
3–6 Moderate
6–8 Good
8–10 Strong
Paras Healthcare IPO Category-wise Subscription
Shares offered, bid & amount
| Category | Sub (x) | Offered | Bid For |
|---|---|---|---|
| QIB | 3.25 | 6,277,056 | 20,381,592 |
| NII / HNI | 0.69 | 3,138,528 | 2,166,507 |
| Retail (RII) | 2.10 | 2,092,352 | 4,395,657 |
| Total | 2.34 | 11,507,936 | 26,943,756 |
* Amount calculated at upper price band (₹693) · ** Total includes all investor categories
Paras Healthcare IPO Application Sizing
Minimum investment by category
Retail Investors ?
Min. Lots
1
Shares / Lot
21
Min. Investment
14,553
HNI Investors ?
Min. Lots
14
Min. Shares
294
Min. Investment
203,742
bHNI (>₹10L) ?
Min. Lots
69
Min. Shares
1,449
Min. Investment
1,004,157
Paras Healthcare IPO Valuation — EPS & P/E
Pre & post-issue metrics
Pre-Issue EPS ?
₹ 4
Post-Issue EPS ?
₹ 18
Pre-Issue P/E ?
160 x
Post-Issue P/E ?
38 x
Paras Healthcare IPO Timeline & Key Dates
- 1 Initiation of Refund 27 Oct 2026
- 2 Credit of Shares to Demat 27 Oct 2026
Investor Interpretation
- The IPO P/E of 38x reflects a moderate valuation relative to typical market ranges.
- Pre-issue EPS of ₹4 compares to post-issue EPS of ₹18 after dilution.
This IPO has relatively lower interest or stretched valuation. Proceed with thorough research and caution.
Paras Healthcare IPO Subscription FAQs
Paras Healthcare IPO is subscribed 2.34x overall (Retail 2.10x, QIB 3.25x, NII/HNI 0.69x).
The retail (RII) portion of Paras Healthcare IPO is subscribed 2.10x.
Paras Healthcare IPO — QIB 3.25x, NII/HNI 0.69x.
In Paras Healthcare IPO, retail investors can apply for a minimum of 1 lot(s) (₹14,553); HNI/sNII minimum 14 lots (₹203,742); bNII minimum 69 lots (₹1,004,157).
Shares offered by category — QIB 6,277,056 shares, Retail 2,092,352 shares.
Paras Healthcare IPO valuation — pre-issue EPS ₹4.34, post-issue EPS ₹18.37, pre-issue P/E 159.68, post-issue P/E 37.72.
Subscription is shares bid for divided by shares offered in that category. If 10 lakh shares are offered and 50 lakh are bid for, the category is subscribed 5 times. Final numbers are confirmed after the bidding closes.
The NII category covers investors applying for shares outside the retail investor category, while HNI commonly refers to high-value investors within the NII category. Understanding the Paras Healthcare IPO's NII and HNI subscription levels helps investors assess demand for the Paras Healthcare IPO and overall investor interest.
GMP and IPO data are unofficial and for information only — not investment advice. Read the full disclaimer.